Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions Conference Paper uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Arthritis, Rheumatoid
  • Inflammation
  • Interleukin-6
  • Receptors, Interleukin-6

abstract

  • The consensus statement identifies points to consider when using TCZ, regarding indications, contraindications, screening, dose, comedication, response evaluation and safety. The document is aimed at supporting clinicians and informing patients, administrators and payers on opportunities and limitations of IL-6 pathway inhibition.

authors

publication date

  • April 2013

Research

keywords

  • Conference Paper

Identity

Language

  • eng

PubMed Central ID

  • PMC3595138

Digital Object Identifier (DOI)

  • 10.1136/annrheumdis-2012-202469

PubMed ID

  • 23172750

Additional Document Info

start page

  • 482

end page

  • 92

volume

  • 72

number

  • 4